Bibliography
- De Silva AD, Mylonaki M, Rampton DS. Oral iron therapy in inflammatory bowel disease: usage, tolerance, and efficacy. Inflamm Bowel Dis 2003;9:316-20
- Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010;7:599-610
- Dudkowiak R, Neubauer K, Poniewierka E. Hepcidin and its role in inflammatory bowel disease. Adv Clin Exp Med 2013;22:585-91
- Rogler G, Vavricka A. Anemia in inflammatory bowel disease: an under-estimated problem? Front Med 2015;1:58. Available from: http://journal.frontiersin.org/article/10.3389/fmed.2014.00058/full [ Last accessed 16 September 2015]
- Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-6
- Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol 1993;94:174-81
- Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 1996;334:61923
- Dignass AU, Gasche C, Bettenworth D, et al. European Crohn’s and Colitis Organisation [ECCO]. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015;9:211-22
- Iron deficiency anaemia. Assessment, prevention, and control. A guide for programme managers. World Health Organization, Geneva, Switzerland; 2001. Available from: www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/WHO_NHD_01.3/en/ [Last accessed 16 September 2015]
- Lindgren S, Wikman O, Befrits R. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009;44:838-45
- SchrÖ;der O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease_a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005;100:2503-9
- Kulnigg S, GascheC. Systematic review: managing anaemia in Crohn’s disease. Aliment Pharmacol Ther 2006;24:1507-23
- Summary of Product Characteristics for ferrous fumarate 210mg tablets. Amdipharm Mercury Company Limited. Electronic Medicines Compendium, Leatherhead, UK; 2014. Available from: www.medicines.org.uk/emc/medicine/27076 [Last accessed 16 September 2015]
- Summary of Product Characteristics for ferrous gluconate 300mg tablets. Kent Pharmaceuticals Ltd. Electronic Medicines Compendium, Leatherhead, UK; 2014. Available from: www.medicines.org.uk/emc/medicine/26313 [Last accessed 16 September 2015]
- Summary of Product Characteristics for ferrous sulphate 200mg coated tablets. Wockhardt UK Ltd. Medicines & Healthcare products Regulatory Agency, London, UK; 2015. Available from: www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1425619562176.pdf [Last accessed 16 September 2015]
- de Silva AD, Tsironi E, Feakins RM, Rampton DS. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther 2005;22:1097-105
- Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008;103:1182-92
- Abhyankar A, Moss AC. Iron replacement in patients with inflammatory bowel disease: A systematic review and meta-analysis. Inflamm Bowel Dis 2015;21:1976-81
- Beigel F, LÖ;hr B, Laubender RP, et al. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease. Digestion 2012;85:47-54
- New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. European Medicines Agency, London, UK; 2013. Available from: www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144874.pdf [Last accessed 16 September 2015]
- Santiago P . Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview. Scientific World Journal 2012;2012:846824
- Gasche C , Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007;13:1545-53
- Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: Results from a phase-3 clinical trial program. Inflamm Bowel Dis 2015;21:579-88
Phase III data.
- Harvey RS, Reffitt DM, Doig LA, et al. Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron. Aliment Pharmacol Ther 1998;12:845-8
Early clinical report of ferric maltol in patients intolerant to oral ferrous sulfate.
- Bokemeyer B, Krummenerl A, Maaser C, et al. A pharmacokinetic study of ferric maltol (ST10; Fe-M) at 3 dosages in inflammatory bowel disease (IBD) patients with iron deficiency Poster 581. Presented at 10th Congress of European Crohn’s and Colitis Organisation; 18 – 21 February 2015, Barcelona, Spain
Recent pharmacokinetic data.
- Conrad ME, Umbreit JN. Iron absorption and transport−an update. Am J Hematol 2000;64:287-98
- Toblli JE, Cao G, Olivieri L, Angerosa M. Comparative study of gastrointestinal tract and liver toxicity of ferrous sulfate, iron amino chelate and iron polymaltose complex in normal rats. Pharmacology 2008;82:127-37
- Singh RK, Barrand MA. Lipid peroxidation effects of a novel iron compound, ferric maltol. A comparison with ferrous sulphate. J Pharm Pharmacol 1990;42:276-9
- Kortman GA, Raffatellu M, Swinkels DW, Tjalsma H. Nutritional iron turned inside out: intestinal stress from a gut microbial perspective. FEMS Microbiol Rev 2014;38:1202-34
- Barrand MA, Callingham BA. Evidence for regulatory control of iron uptake from ferric maltol across the small intestine of the rat. Br J Pharmacol 1991;102:408-14
- Reffitt DM, Burden TJ, Seed PT, et al. Assessment of iron absorption from ferric trimaltol. Ann Clin Biochem 2000;37:457-66
- Kelsey SM, Blake DR, Hider RC, et al. Absorption of ferric maltol, a novel ferric iron compound, in iron-deficient subjects. Clin Lab Haematol 1989;11:287-8
- Barrand MA, Callingham BA, Dobbin P, Hider RC. Dissociation of a ferric maltol complex and its subsequent metabolism during absorption across the small intestine of the rat. Br J Pharmacol 1991;102:723-9
- Data on file, Iron Therapeutics (Switzerland) AG
- Kelsey SM , Hider RC, Bloor RJ, et al. Absorption of low and therapeutic doses of ferric maltol, a novel ferric iron compound, in iron deficient subjects using a single dose iron absorption test. J Clin Pharm Ther 1991;16:117-22
- Champagne ET . Low gastric hydrochloric acid secretion and mineral bioavailability. Adv Exp Med Biol 1989;249:173-84
- Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J 2004;97:887-9
- Ajmera AV, Shastri GS, Gajera MJ, Judge TA. Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole. Am J Ther 2012;19:185-9
- Wong G, Howard K, Hodson E, et al. An economic evaluation of intravenous versus oral iron supplementation in people on haemodialysis. Nephrol Dial Transplant 2013;28:413-20
- Semrin G, Fishman DS, Bousvaros A, et al. Impaired intestinal iron absorption in Crohn’s disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis 2006;12:1101-6
- Krayenbuehl PA, Battegay E, Breymann C, et al. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011;118:3222-7
- Vaucher P, Druais PL, Waldvogel S, Favrat B. Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial. CMAJ 2012;184:1247-54
- Anker SD , Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48
- Evstatiev R, Alexeeva O, Bokemeyer B, et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:269–77